Recent Advances and Research Progress in Biomarkers for Chronic Graft Versus Host Disease.

[1]  F. Bonifazi,et al.  A Multiparameter Prognostic Risk Score of Chronic GVHD based on CXCL10 and Plasmacytoid DC (pDC) levels in the Peripheral Blood at 3 months after Allogeneic Hematopoietic Stem Cell Transplantion (HSCT). , 2023, Transplantation and cellular therapy.

[2]  Xiaoqi Wang,et al.  Recent advances in ocular graft-versus-host disease , 2023, Frontiers in Immunology.

[3]  G. Cuvelier,et al.  Circulating Cell Free Mitochondrial DNA As a Diagnostic and Prognostic Biomarker in Chronic and Late Acute Graft-versus-Host Disease in Children. , 2022, Experimental hematology.

[4]  J. Chewning,et al.  A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study , 2022, Blood advances.

[5]  Xiaohui Zhang,et al.  Current status and prospects of hematopoietic stem cell transplantation in China , 2022, Chinese medical journal.

[6]  T. Tvedt,et al.  MicroRNA serum profiles and chronic graft-versus-host disease , 2022, Blood advances.

[7]  Yue Han,et al.  [The Role and Mechanism of Tfh and B Cell in Human Chronic Graft-Versus-Host-Disease]. , 2022, Zhongguo shi yan xue ye xue za zhi.

[8]  F. Heinemann,et al.  Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival , 2021, Frontiers in Immunology.

[9]  F. Farina,et al.  Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients , 2021, Frontiers in Oncology.

[10]  E. Mischak-Weissinger,et al.  Profiling Tissue and Biofluid miR-155-5p, miR-155*, and miR-146a-5p Expression in Graft vs. Host Disease , 2021, Frontiers in Immunology.

[11]  Rajiv Kumar,et al.  Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD , 2021, Blood cancer journal.

[12]  Sujun Gao,et al.  Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis. , 2021, Hematology.

[13]  R. Wäsch,et al.  Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host disease , 2020, Bone Marrow Transplantation.

[14]  J. Duyster,et al.  Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease , 2020, Bone Marrow Transplantation.

[15]  A. Costa-Pereira,et al.  Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker , 2020, Future science OA.

[16]  Y. Ye,et al.  Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation , 2020, Frontiers in Immunology.

[17]  Zhenmin Liu,et al.  Analysis of serum and salivary cytokines among patients with oral cGVHD after Allo-HSCT. , 2020, Oral diseases.

[18]  S. Steinberg,et al.  Clinical characteristics and cytokine biomarkers in patients with chronic graft‐vs‐host disease persisting seven or more years after diagnosis , 2020, American journal of hematology.

[19]  M. Hummel,et al.  CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease , 2020, Transplantation.

[20]  Lin Wang,et al.  Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation , 2019, Journal of Zhejiang University-SCIENCE B.

[21]  P. Lai,et al.  青蒿琥酯调控Th17/Treg平衡抑制慢性移植物抗宿主病的实验研究 , 2019, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[22]  M. C. Aguilera-Morillo,et al.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. , 2018, Blood advances.

[23]  Satoshi Takahashi,et al.  Circulating monocyte subsets in human chronic graft-versus-host disease , 2018, Bone Marrow Transplantation.

[24]  B. Blazar,et al.  MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. , 2018, Blood.

[25]  S. Paczesny,et al.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease , 2018, Expert review of clinical immunology.

[26]  H. Dolstra,et al.  Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword , 2018, British journal of haematology.

[27]  J. Lipton,et al.  Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD , 2018, Bone Marrow Transplantation.

[28]  M. Beksac,et al.  Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation , 2018, Annals of Hematology.

[29]  H. Sengeløv,et al.  Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation , 2018, Front. Immunol..

[30]  D. Miklos,et al.  Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  E. Weissinger,et al.  Biomarkers in chronic graft-versus-host disease: quo vadis? , 2018, Bone Marrow Transplantation.

[32]  B. Blazar,et al.  Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.

[33]  I. Fernández,et al.  Prehematopoietic Stem Cell Transplantation Tear Cytokines as Potential Susceptibility Biomarkers for Ocular Chronic Graft-Versus-Host Disease. , 2017, Investigative ophthalmology & visual science.

[34]  S. Paczesny,et al.  B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality , 2017, Bone Marrow Transplantation.

[35]  M. Rafei,et al.  Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation , 2017, Journal of Hematology & Oncology.

[36]  J. Ritz,et al.  PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. , 2017, Blood.

[37]  C. Königs,et al.  Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections , 2017, Front. Immunol..

[38]  J. Ritz,et al.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  M. Sarwal,et al.  A combined biomarker and clinical panel for chronic graft versus host disease diagnosis , 2016, The journal of pathology. Clinical research.

[40]  V. Lazarevic,et al.  Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  R. Başar,et al.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. , 2016, Blood.

[42]  J. Storek,et al.  Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation , 2016, PloS one.

[43]  B. Storer,et al.  Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. , 2016, Blood.

[44]  J. Ritz,et al.  Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. , 2016, Blood.

[45]  J. Wagner,et al.  Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  C. Morimoto,et al.  Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate. , 2016, Critical reviews in immunology.

[47]  A. Roberts,et al.  Targeting GM-CSF in inflammatory diseases , 2016, Nature Reviews Rheumatology.

[48]  Junfei Jin,et al.  MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. , 2015, Blood.

[49]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .

[50]  K. Lam,et al.  Mir-17–92 regulates bone marrow homing of plasma cells and production of immunoglobulin G2c , 2015, Nature Communications.

[51]  M. Robin,et al.  CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. , 2015, Blood.

[52]  W. Pickl,et al.  CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.

[54]  W. Swaim,et al.  Comparative analysis of FoxP3+ regulatory T cells in the target tissues and blood in chronic graft versus host disease , 2014, Leukemia.

[55]  K. Yazdanbakhsh.  cGVHD B(r)egs to differ. , 2014, Blood.

[56]  K. Rezvani,et al.  Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. , 2014, Blood.

[57]  M. Tanimoto,et al.  Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease , 2014, The Journal of Immunology.

[58]  J. Byrd,et al.  Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. , 2014, Blood.

[59]  Yuan Fang,et al.  Serum microRNA155 is increased in patients with acute graft‐versus‐host disease , 2014, Clinical transplantation.

[60]  P. Liu,et al.  Clinical significance of anti-endothelial cell antibody in allogeneic hematopoietic stem cell transplantation recipients with graft-versus-host disease , 2014, International Journal of Hematology.

[61]  P. Chevallier,et al.  Increased Th17/Treg ratio in chronic liver GVHD , 2014, Bone Marrow Transplantation.

[62]  A. J. Wilson,et al.  Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation , 2013, Genes and Immunity.

[63]  P. Raman,et al.  The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. , 2013, Blood.

[64]  A. Lyon,et al.  IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD , 2013, Bone Marrow Transplantation.

[65]  G. Dekan,et al.  CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. , 2013, Blood.

[66]  Xiao-jun Huang,et al.  Donor Th17 cells and IL‐21 may contribute to the development of chronic graft‐versus‐host disease after allogeneic transplantation , 2013, European journal of immunology.

[67]  R. Jenq,et al.  Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. , 2012, Immunity.

[68]  P. Taylor,et al.  Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. , 2011, Blood.

[69]  J. Rozmus,et al.  Biomarkers in chronic graft-versus-host disease , 2011, Expert review of hematology.

[70]  J. Gołąb,et al.  Interleukin 15 as a promising candidate for tumor immunotherapy. , 2011, Cytokine & growth factor reviews.

[71]  G. Corazza,et al.  Role of IL-15 in immune-mediated and infectious diseases. , 2011, Cytokine & growth factor reviews.

[72]  S. Sampaio,et al.  XM-ONE detection of endothelium cell antibodies identifies a subgroup of HLA-antibody negative patients undergoing acute rejection. , 2011, Transplantation proceedings.

[73]  J. Reynolds,et al.  Localized adenocarcinoma of the esophagogastric junction--is there a standard of care? , 2010, Cancer treatment reviews.

[74]  E. Ramsay,et al.  Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[75]  R. Storb,et al.  Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[76]  Thomas M Braun,et al.  Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin , 2008, Science Translational Medicine.

[77]  Soo-Jung Lee,et al.  Clinical Significance of Autoantibody Expression in Allogeneic Stem-Cell Recipients , 2009, Transplantation.

[78]  F. Dieli,et al.  Analysis of Memory and Effector CD8+ T Cell Subsets in Chronic Graft-versus-Host Disease , 2009, International journal of immunopathology and pharmacology.

[79]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[80]  A. Fauci,et al.  The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.

[81]  K. Rajewsky,et al.  BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells , 2008, Proceedings of the National Academy of Sciences.

[82]  G. Cuvelier,et al.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. , 2008, Blood.

[83]  Rudolf Jaenisch,et al.  Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters , 2008, Cell.

[84]  N. Lee,et al.  Single Nucleotide Polymorphism of CC Chemokine Ligand 5 Promoter Gene in Recipients May Predict the Risk of Chronic Graft-Versus-Host Disease and its Severity After Allogeneic Transplantation , 2007, Transplantation.

[85]  Kyung-Su Park,et al.  Lupus enteritis: clinical characteristics, risk factor for relapse and association with anti-endothelial cell antibody , 2007, Lupus.

[86]  J. Passweg,et al.  HLA and KIR polymorphisms affect NK-cell anti-tumor activity. , 2007, Trends in immunology.

[87]  S. Svegliati,et al.  Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. , 2007, Blood.

[88]  R. Fanin,et al.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. , 2006, Experimental hematology.

[89]  H. Tagawa,et al.  A microRNA cluster as a target of genomic amplification in malignant lymphoma , 2005, Leukemia.

[90]  P. Rubegni,et al.  Extracorporeal photopheresis affects interleukin (IL)‐10 and IL‐12 production by monocytes in patients with chronic graft‐versus‐host disease , 2005, The British journal of dermatology.

[91]  A. Kalloo,et al.  Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. , 2002, Endoscopy.

[92]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[93]  Y. Aizawa,et al.  Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation , 2000, Bone Marrow Transplantation.

[94]  S. Burdach,et al.  Decreased interleukin 10 and increased interferon-γ production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation , 1997, Bone Marrow Transplantation.